Novel therapeutic approaches to cancer immunotherapy and mRNA vaccines technology: a review

Abstract Messenger ribonucleic acid (mRNA)-based vaccines have good patient tolerability, and the encoded molecules are readily accessible and versatile for potential future applications in cancer treatment. The development of lipid nanoparticles in conjunction with mRNA engineering may enable full application of cancer vaccines in immunotherapy to boost immune responses. These vaccines are easy to handle, quickly to produce in large quantities, and flexible enough to express full-length antigens with distinct epitopes without being restricted by the major histocompatibility complex (MHC). The use of mRNA vaccines in immunological and cancer treatments have advanced over the past few decades from theoretical conjecture to clinical practices. The high potency, quick development, inexpensive manufacture, and safe delivery of these vaccines provide a number of benefits over conventional vaccination methods. As luck would have it, most of the worries associated with all preexisting cancer treatments have been allayed by recent technological developments, which have led to the creation of many mRNA vaccine platforms against cancer and infectious diseases like COVID-19 virus. As a viable substitute for traditional vaccination methods and cancer treatments, this study emphasized the efficacy of mRNA vaccines for cancer immune responses. The goal of this paper is to present a comprehensive and in-depth analysis of mRNA vaccines, covering their modes of action and possible uses in cancer immunotherapy. The paper also examined the present status of mRNA vaccine technology and suggest potential paths for the advancement and application of this exciting vaccination platform as a common therapeutic choice. The study intends to further this ground-breaking method of treating cancer by offering a thorough overview and critical examination of mRNA vaccines.